Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for adhd
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:
hyperactivity and impulsiveness
Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).
Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).
Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.
Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).
Attention-deficithyperactivitydisorder. Attention-deficithyperactivitydisorder (ADHD), like other psychiatric disorders, represents an evolving construct that has been refined and developed over the past several decades in response to research into its clinical nature and structure. The clinical presentation and course of the disorder have been extensively characterised. Efficacious medication-based treatments are available and widely used, often alongside complementary psychosocial (...) provide an account of the diagnosis, epidemiology, and treatment of ADHD from the perspective of both the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders and the eleventh edition of the International Classification of Diseases. Second, we review the progress in our understanding of the causes and pathophysiology of ADHD on the basis of science over the past decade or so. Finally, using these discoveries, we explore some of the key challenges to both the current models
M, Gasior M, Gao J, Giblin J. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivitydisorder. Postgrad Med 2011; 123(2): 169-176. 16. Shire Development. A phase 4, randomized, double-blind, multi-center, placebocontrolled, parallel-group study evaluating the safety and efficacy of SPD489 on executive function (self-regulation) behaviors in adults with attention-deficit/hyperactivitydisorder (ADHD) reporting clinically significant impairment of real-world (...) executive function behavior: study SPD489-403; clinical study report [unpublished]. 2010. 17. Shire Development. A phase 4, randomized, double-blind, multi-center, placebo- controlled, parallel-group study evaluating the safety and efficacy of SPD489 on executive function (Self-regulation) behaviors in adults with attention-deficit/hyperactivitydisorder (ADHD) reporting clinically significant impairment of real-world executive function behavior: study SPD489-403; clinical study protocol [unpublished
a suboptimal response to stimulants. PBS listing Authority Required (Streamlined) On 1 March 2019, guanfacine (Intuniv) was listed on the PBS as an Authority Required (Streamlined) listing. It was listed as an adjunctive treatment to stimulant medicines in patients with attentiondeficithyperactivitydisorder (ADHD). , To receive subsidised treatment, patients must have residual moderate to severe symptoms despite receiving a maximum tolerated dose (MTD) of dexamfetamine, methylphenidate (...) submission for guanfacine are summarised below. ADHD-RS-IV: The AttentionDeficitHyperactivityDisorder Rating Scale IV is an investigator-rated questionnaire. It consists of 18 items that measure ADHD symptoms according to DSM-IV criteria. Scores range from 0 (never) to 54 (always). A between-group minimally clinically important difference (MCID) has not been fully established, but a 30% mean total score change (or 5.2–7.7 points) has been suggested in some publications. CGI-S: For the Clinical Global
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/HyperactivityDisorder in Children and Adolescents Attention-deficit/hyperactivitydisorder (ADHD) is 1 of the most common neurobehavioral disorders of childhood and can profoundly affect children's academic achievement, well-being, and social interactions. The American Academy of Pediatrics first published clinical recommendations for evaluation and diagnosis of pediatric ADHD in 2000; recommendations (...) for treatment followed in 2001. The guidelines were revised in 2011 and published with an accompanying process of care algorithm (PoCA) providing discrete and manageable steps by which clinicians could fulfill the clinical guideline's recommendations. Since the release of the 2011 guideline, the Diagnostic and Statistical Manual of Mental Disorders has been revised to the fifth edition, and new ADHD-related research has been published. These publications do not support dramatic changes to the previous
. However, from the perspective of a health system focused on quality improvement (QI), such large evidence reports with wide scope are difficult to implement within a QI initiative. Methods. We consulted with two health systems to identify a published EPC report on a topic of interest to future quality initiatives. After identifying the target report on attentiondeficithyperactivitydisorder (ADHD), we gathered feedback from the health system to determine what information on ADHD treatments (...) in a quality improvement initiative. 8 Abbreviations and Acronyms ADHDAttention-Deficit/HyperactivityDisorder EPC Evidence-based Practice Center QI Quality Improvement 9 References 1. Kemper AR, Maslow GR, Hill S, et al. AHRQ Comparative Effectiveness Reviews. AttentionDeficitHyperactivityDisorder: Diagnosis and Treatment in Children and Adolescents. Comparative Effectiveness Review No. 203. (Prepared by the Duke University Evidence-based Practice Center under Contract No. 290-2015- 00004-I.) AHRQ
found below this term in the MeSH hierarchy; [MAJR] = MeSH Major Topic; [TIAB] = Title or abstract; [TI] = Title; [AU] = Author; [TW] = Text Word; Systematic[SB] = Filter for retrieving systematic reviews; * = Truncation Search terms Items found Population: 1. “AttentionDeficit and DisruptiveBehaviorDisorders”/ 2747 2. AttentionDeficitDisorder with Hyperactivity/ 27226 3. "Attentiondeficit* ".ab,kw,ti. 27852 4. ("Attentiondeficit*" adj6 hyper*).ab,kw,ti. 24598 5. ("ADHD" or "ADDH").ab,kw,ti (...) found Population: 1. [mh “AttentionDeficit and DisruptiveBehaviorDisorders”] 2809 2. [mh “AttentionDeficitDisorder with Hyperactivity”] 2482 3. (“AttentionDeficitDisorder*”:ab,ti) 3751 4. ("Attentiondeficit*":ab,ti NEAR hyper*:ab,ti) 3529 5. (“adhd”:ti,ab,kw OR “addh”:ti,ab) 4168 6. 1 OR 2 OR 3 OR 4 OR 5 5506 7. [mh "Autistic Disorder"] 867 8. [mh "Autism Spectrum Disorder"] 1211 9. ("Autism" or Autist* or "ASD" OR "Autism spectrum*"):ti,ab 3467 10. 7 OR 8 OR 9 3523 11. 6 OR 10 8787
Suicidal behaviour among persons with attention-deficithyperactivitydisorder Persons diagnosed with attention-deficithyperactivitydisorder (ADHD) have been found to have an increased risk of suicidal behaviour, but the pathway remains to be thoroughly explored.AimsTo determine whether persons with ADHD are more likely to present with suicidal behaviour (i.e. suicide attempts and deaths by suicide) if they have a comorbid psychiatric disorder.Using nationwide registers covering the entire (...) suicidal outcomes were observed. This group was found to have an IRR of suicidal behaviour of 4.7 (95% CI, 4.3-5.1) compared with those without ADHD. Persons with ADHD only had a 4.1-fold higher rate (95% CI, 3.5-4.7) when compared with those without any psychiatric diagnoses. For persons with ADHD and comorbid disorders the IRR was higher yet (IRR: 10.4; 95% CI, 9.5-11.4).This study underlines the link between ADHD and an elevated rate of suicidal behaviour, which is significantly elevated by comorbid
Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study The benefits of long-term use of methylphenidate treatment in children and adolescents with attentiondeficithyperactivitydisorder (ADHD), as frequently prescribed in clinical practice, are unclear. The authors investigated whether methylphenidate remains beneficial after 2 years of use.Ninety-four children and adolescents (ages 8-18 years) who had been (...) . The ADHD-RS inattention subscale and the CTRS-R:S ADHD index and hyperactivity subscale also deteriorated significantly more in the discontinuation group. The CGI-I indicated worsening in 40.4% of the discontinuation group, compared with 15.9% of the continuation group.Continued treatment with methylphenidate remains effective after long-term use. Some individual patients may, however, be withdrawn from methylphenidate without deterioration. This finding supports guideline recommendations that patients
Social skills training for attentiondeficithyperactivitydisorder (ADHD) in children aged 5 to 18 years. Attentiondeficithyperactivitydisorder (ADHD) in children is associated with hyperactivity and impulsivity, attention problems, and difficulties with social interactions. Pharmacological treatment may alleviate the symptoms of ADHD but this rarely solves difficulties with social interactions. Children with ADHD may benefit from interventions designed to improve their social skills. We (...) examined the benefits and harms of social skills training on social skills, emotional competencies, general behaviour, ADHD symptoms, performance in school of children with ADHD, and adverse events.To assess the beneficial and harmful effects of social skills training in children and adolescents with ADHD.In July 2018, we searched CENTRAL, MEDLINE, Embase, PsycINFO, 4 other databases and two trials registers.We also searched online conference abstracts, and contacted experts in the field
Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. The prescription use of the stimulants methylphenidate and amphetamine for the treatment of attentiondeficit-hyperactivitydisorder (ADHD) has been increasing. In 2007, the Food and Drug Administration mandated changes to drug labels for stimulants on the basis of findings of new-onset psychosis. Whether the risk of psychosis in adolescents and young adults with ADHD differs among various stimulants has not been extensively (...) studied.We used data from two commercial insurance claims databases to assess patients 13 to 25 years of age who had received a diagnosis of ADHD and who started taking methylphenidate or amphetamine between January 1, 2004, and September 30, 2015. The outcome was a new diagnosis of psychosis for which an antipsychotic medication was prescribed during the first 60 days after the date of the onset of psychosis. To estimate hazard ratios for psychosis, we used propensity scores to match patients who
Squeeze balls for people with attentiondeficithyperactivitydisorder Squeeze balls and fidget devices - Health Technology Wales > Squeeze balls and fidget devices Squeeze balls and fidget devices Topic Status Incomplete Squeeze balls for people with attentiondeficithyperactivitydisorder. Summary Health Technology Wales researchers searched for evidence on the effectiveness of squeeze balls or other fidget devices in adults with attentiondeficithyperactivitydisorder. Insufficient
name or password? You are here Attention-deficit/hyperactivedisorder: missing the bull’s eye Article Text Letter Attention-deficit/hyperactivedisorder: missing the bull’s eye Chaithanya Leon , Ratna Sharma , Simran Kaur Statistics from Altmetric.com The article by Cortese and Coghill comprehensively highlights the recent advances in attention-deficit/hyperactivitydisorder (ADHD) research in terms of causes, diagnosis and treatment. 1 The effort to understand the current status of the research (...) Attention-deficit/hyperactivedisorder: missing the bull’s eye Attention-deficit/hyperactivedisorder: missing the bull’s eye | Evidence-Based Mental Health Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user
In March 2018, the National Institute for Health and Care Excellence (NICE) updated its guideline (NG87) on diagnosing and managing attention-deficithyperactivitydisorder (ADHD), 1 and its in-house systematic reviews on the efficacy and adverse events of pharmacological treatments for ADHD. 2 3 The guideline recommends methylphenidate as the first-line pharmacological treatment for children over five, adolescents and adults with ADHD and lisdexamfetamine for adults only (recommendations under section (...) 1.7). 1 An appointed NICE committee formulated the recommendations based on clinical experience, drug licensing regulations and the systematic review evidence (developed in concert with the National Guideline Centre). 4 The NICE committee conclude that methylphenidate and lisdexamfetamine provide clinically important benefits to patients with ADHD compared with placebo and other drugs (p. 47). 1 ADHD is a neurodevelopmental disorder characterised by excessive hyperactivity, impulsivity
prescribing: cross-sectional database study of a national surveillance network Uy Hoang , Anthony C James , Harshana Liyanage , Simon Jones , , Mark Joy , Mitch Blair , Michael Rigby , Simon de Lusignan , Statistics from Altmetric.com Background and aims Attentiondeficithyperactivitydisorder (ADHD) is the most common psychiatric disorder in childhood and adolescents. ADHD is associated with failure in the attainment of many normal developmental milestones and can result in children experiencing school (...) and Surveillance Centre practices. ADHD, attentiondeficithyperactivitydisorder. Only 26 children with HKCD were recorded in the RCGP RSC network. Age of diagnosis of ADHD The mean age of first diagnosis with ADHD was 10.5 years (95% CI 10.1 to 10.9, median 10, IQR 9.0–11.9). There was also wide inter-practice variation in the age of first diagnosis of ADHD with the diagnosis being made anywhere between 5 and 17 years of age across RCGP RSC practices. Prescribing of stimulant medications in children
AttentionDeficit-HyperactivityDisorder and Month of School Enrollment. Younger children in a school grade cohort may be more likely to receive a diagnosis of attentiondeficit-hyperactivitydisorder (ADHD) than their older peers because of age-based variation in behavior that may be attributed to ADHD rather than to the younger age of the children. Most U.S. states have arbitrary age cutoffs for entry into public school. Therefore, within the same grade, children with birthdays close (...) to the cutoff date can differ in age by nearly 1 year.We used data from 2007 through 2015 from a large insurance database to compare the rate of ADHD diagnosis among children born in August with that among children born in September in states with and states without the requirement that children be 5 years old by September 1 for enrollment in kindergarten. ADHD diagnosis was determined on the basis of diagnosis codes from the International Classification of Diseases, 9th Revision. We also used prescription
disorder or ADHD Share: Reading time approx. 6 minutes There are theories that different types of nutritional or dietary interventions, where specific food items are excluded from the diet or where nutritional supplements are added, may affect the symptoms of persons with AttentionDeficitHyperactivityDisorder (ADHD) or autism spectrum disorder. This applies, for example, to gluten-free and casein-free diet, ketogenic diet (a strict option of a low carbohydrate diet) or diet where sugar or various (...) ): AHRQ (US Agency for Healthcare Research and Quality); 2018. Catala-Lopez F, Hutton B, Nunez-Beltran A, Page MJ, Ridao M, Macias Saint-Gerons D, et al. The pharmacological and non-pharmacological treatment of attentiondeficithyperactivitydisorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One 2017;12:e0180355. Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. Nonpharmacological interventions for ADHD
ADHD in children and youth: Part 3?Assessment and treatment with comorbid ASD, ID, or prematurity Attention-deficithyperactivitydisorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed (...) , evidence-based decisions to enhance care of children and youth with this condition. Specific topics reviewed in Part 3, which focuses on associated autism spectrum disorder, intellectual disability, and prematurity, include the challenges of diagnostic assessment, common presentations, the role of genetics, and treatment, including the benefits of physical activity. Recommendations are based on current guidelines, evidence from the literature, and expert consensus. Keywords: Autism; ADHD; Intellectual
ADHD in children and youth: Part 2?Treatment Attention-deficithyperactivitydisorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed, evidence-based decisions to enhance care of children (...) the literature, and expert consensus. Keywords: ADHD; Adverse effects; Combined interventions; Medication management
ADHD in children and youth: Part 1?Etiology, diagnosis, and comorbidity Attention-deficithyperactivitydisorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed, evidence-based decisions (...) Guidelines Network, and the Eunethydis European ADHD Guidelines Group, were reviewed. Because ADHD is a heterogeneous disorder, comprehensive medical assessment for ADHD should always include a complete history, a physical examination, and a thorough consideration of differential diagnosis and related comorbidities. Specific recommendations for information gathering, testing, and referral are offered. Keywords: Attention-deficithyperactivitydisorder; Comorbidity; Diagnosis; Etiology